Will serputinib/serpatinib be included in the medical insurance directory in 2025?

As of 2025, Selpercatinib (also known as Selpatinib) has been officially launched in China for the treatment of non-small cell lung cancer (NSCLC) and thyroid cancer and other related tumors with RET gene fusion. However, the drug has not yet been included in the national medical insurance catalog, which means that if patients choose to use the drug for treatment, they need to bear all the drug costs out of their own pocket, which is a relatively heavy financial burden.

In the domestic market, Seputinib is sold in a box of 80mg*56 pills, and its price usually exceeds RMB 10,000. The specific price may vary slightly depending on the hospital and supply channels. Because they do not enjoy the medical insurance reimbursement policy, patients face greater financial pressure during long-term medication, especially when the treatment period needs to be maintained for a long time. Although some places may provide short-term help through charity assistance programs, overall the high cost remains a major obstacle to clinical use.

Compared with the domestic market, the price of original research Septinib in overseas markets is more expensive. The price of a box often ranges from 20,000 yuan to more than 100,000 yuan, and is greatly affected by exchange rate changes. Therefore, some patients will choose to purchase more cost-effective generic drugs through overseas channels to reduce their financial burden. It is worth noting that although the price is lower, when purchasing drugs overseas, it is necessary to ensure that the channels are formal and the drugs are authentic to ensure drug safety.
At present, generic versions of Seputinib have been launched overseas. For example, the 40mg*120-tablet generic drug produced by a Lao pharmaceutical factory sells for about more than 2,000 yuan, which is much lower than the original drug. These generic drugs are basically the same as the original drugs in terms of ingredients and efficacy, making them an alternative choice for some patients. Overall, although seputinib has not yet been included in medical insurance, its clinical demand continues to grow. In the future, with policy adjustments, it is expected to be included in the medical insurance system to further improve accessibility.
Reference: https://en.wikipedia.org/wiki/Selpercatinib